FDA Approves Ranbaxy Drug for Infection
Posted on: Thursday, 14 December 2006, 21:00 CST
Generic drug maker Ranbaxy has received approval from the FDA to manufacture and market cefprozil tablets for infection.
The FDA has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Cefzil tablets of Bristol-Myers Squibb. According to Ranbaxy, total annual market sales for cefprozil tablets were $76.6 million.
Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in certain conditions, including tonsillitis, sinusitis, bronchitis and skin infections.
"Ranbaxy is pleased to be granted approval for Cefprozil tablets which represents yet another addition to our ever-growing product portfolio of anti-infectives that will be available as an affordable generic alternative to the brand equivalent," according to Jim Meehan, vice president of Sales and Marketing for Ranbaxy, USA.
Ranbaxy plans to bring this product to the market in early 2007 during the height of the respiratory season.
Source: Datamonitor
Related Articles
- Heritage Pharmaceuticals Launches Generic Inderal Tablets
- Breckenridge Pharmaceutical, Inc. And Chemo/Liconsa (Spain) Agree to Develop and Market Generic ANDA
- Absolute Software Extends Embedded Anti-Theft Security to Tablet Computing Market
- TabletKiosk Launches Eo TufTab(TM) New Semi-Ruggedized Solution for Mobile Computing
- Ranbaxy Cleared to Market Cefzil Generic
- Teva and Ranbaxy Win FDA Approval for Generic Zocor
- In-Stat Reports Tablet PC Market to Exceed $5 Billion in 2009
- In-Stat/MDR Reports Tablet PC Market Will Remain Partially Successful Until Prices Fall
- Xplore Releases iX104(TM) Renegade(TM) to Address Expanding Underserved Tablet PC Market
- Motion Computing Increases Momentum in Worldwide Tablet PC Market Share, Unit Volumes
 |
 |
User Comments (0)
RSS Feeds